Noscendo – tHe company
About us
Noscendo GmbH is the leading global provider of software-based pathogen identification technology. We’ve made it our objective to revolutionise infection diagnostics, thus saving patient lives.
Scores of well-known university hospitals, major regional hospitals and hospital groups are already using DISQVER. We also work with several health insurance providers.
We have already received a host of awards for our pioneering approach. Noscendo was named Health-i Pioneer 2020 by Handelsblatt and Techniker Krankenkasse (TK). The award honours highly innovative ideas in the healthcare sector. In 2019, the scientific project behind DISQVER was awarded the ‘SIK Innovation Prize 2019’ by the Stuttgart Intensive Care Congress (SIK).
DISQVEr together!
Noscendo in numbers
2017
Noscendo founded
2019
Approval of DISQVER analysis platform
2
Sites, Tübingen and Duisburg
News
Updated Duke-ISCVID Criteria for Infective Endocarditis now includes metagenomic Next-Generation-Sequencing (mNGS)
The 2023 Duke-International Society for Cardiovascular Infectious Diseases Criteria for Infective Endocarditis now includes metagenomic next-generation sequencing (mNGS) as a new, useful diagnostic tool. “The field of cardiovascular infectious diseases is witnessing a game-changing development,” says Philip Stevens, CEO of Noscendo, the world’s leading provider of software-based pathogen identification. “This is an important step towards the acceptance of this type of technology in the diagnosis of challenging infections in critically ill patients.”
World Sepsis Day on 13th September: Study on a new, digital pathogen diagnostic tool is evaluated
At least 85,000 people die every year in Germany from Sepsis, the most severe course of an infectious disease - also known commonly as blood poisoning. World Sepsis Day on September 1 3rd draws attention to this. In the case of Sepsis, it is crucial to identify the respective pathogen early and reliably. However, the detection is often not successful with the methods commonly used today. In a maximum of 30 percent of cases, a pathogen is identified using classic blood culture, in sepsis patients who have already been treated with antibiotics often in less than 10 percent of the cases. For this reason, a German-wide project led by the Department of Anaesthesiology and Intensive Care Medicine at Essen University Hospital is investigating how patients can benefit from a new, digital method for identifying pathogens. At the beginning of August 2023, the recruitment phase of this study was completed, earlier than planned and the evaluation of the results started.
Noscendo GmbH given prestigious award as an “Employer Of The Future”
We are incredibly excited to share with you that Noscendo GmbH has been given a prestigious award as an "Employer Of The Future" from the Deutsche Innovationsinstitut für Nachhaltigkeit und Digitalisierung - DIND (The German Innovation Institute for Sustainability...
Team
Dr. Florence Awamu Ndonglack
Customer Success Representative
Dr. Jennifer Axnick
Medical Project Manager
Johannes Becher
Data Engineer
Dr. Marcus Benz
Chief Operating Officer
Dr. Daniel borda-molina
Bioinformatician
Julia Bottlang
Team Lead Production
Christof Brass
Head of Finance
Nico Büker
Software Developer
Sebastian Clanzett
Vice President Bio & Information Technology
Dr. Claudia Disque-Kochem
Enabling Engineer
Irene Gil Farina
Vice President Research & Development
Michelle Fiedler
Technical Employee
Dr. Silke Grumaz
Chief Scientific Officer, Co-Founder
Dr. Peter Haug
Chief Strategy Officer, Co-Founder
Ian Hill
Business Development Manager
Renè Hennig
Team Lead Frontend
Dr. Rafael Holzem
Quality Management Representative
Scott G. Hopkins
Sales Operations Director
Mattias Horn
Senior Solution Architect
Dr. Petra Horvatek
Diagnostic Liaison Manager
Vanessa Huissel
Technician
Anne-Caroline Joly
Field Application Scientist
Thomas Kästner
Head of IT Operations
Sabine Kießling-Parr
Key Account Manager
Dr. Philipp Kirstahler
Bioinformatician
Dr. Matthias Klaften
Head of Real World Evidence
Michael Klomfass
Senior IT Operator
Christina Koumourzi-Ridil
Vice President People
Silas Krug
Software Developer
Myriam Livrozet
Business Development Manager
Gabriele Magliano
Senior IT Operator
Dr. Sonia Mazitelli
Scientist
MARKUS MOOCK
Research Assistant
Dr. Andreas Moritz
Automation Scientist
Dr. Harm Müller
Key Account Manager
Ulrike Neder
Team Lead Data Analytics
Marco Pietschmann
Vice President Digital Integration
Philip Pohl
Technician
Dr. med. Klaus Rensing, MBA
Head of Medical Affairs D/A/CH
Joshua Richenhagen
Software Developer
Johannes Ristau, PhD
Senior Field Application Scientist
Benjamin Ruff
IT Technician
Jörg Schäfer
Requirements Engineer
Katja Siepmann
Accountant in Finance & Controlling
Dr. Thomas Smylla
Scientist
Franziska Stephan
Technician
Dr. Philip Stevens
Chief Executive Officer, Co-Founder
Darren Tomlinson
Vice President Marketing
Dr. Sandra Unsleber
Scientist
Frederic Vigier
Sales Business Development Manager
Maria Watters
Chief Commercial Officer
Strategic And Scientific Advisory Board
Prof. Dr. Arndt von Haeseler
Prof. von Haeseler is Head of CIBIV (Center for Integrative Bioinformatics Vienna) at the Max Perutz Labs, where he also served as the scientific director. In 2015, von Haeseler was elected as a corresponding member in Austria of the mathematics and science class of the Austrian Academy of Sciences.
Dr. Trevor Hawkins
Dr Hawkins’ 25+ year career in healthcare has included business, academic innovation and entrepreneurship. Dr Hawkins was previously Director of the Human Genome Project for the US DOE, and has held senior executive roles at Siemens Healthcare, Philips, GE Healthcare and Amersham.
Prof. Dr. James Rothman
Prof. Rothman is a highly distinguished biochemist and Sterling Professor of Cell Biology at Yale University who was awarded the 2013 Nobel Prize in Physiology/Medicine. Prof. Rothman serves, among other positions, as Chair of the Yale School of Medicine’s Department of Cell Biology and is the Director and founder of the Nanobiology Institute on Yale’s new West Campus.
Prof. Dr. Felix Wieland
Prof. Wieland is an elected Member of the Academia Europea and the National Academy of Sciences, Leopoldina, as well as an honorary member of the Charité (Medical Faculty of Humboldt University Berlin) and is a Senior Professor for Biochemistry at Heidelberg University. Prof. Wieland’s main areas of research are Enzymology, Glycobiology and Molecular Membrane Biology, including the specificity of lipid-protein interactions.
